

However, this is technically difficult because strong nuclear localization signals in the DBD and hinge region prevent the membrane localization of longer constructs, even though the membrane-targeting signal was attached to them (data not shown).

Another limitation of this purification method was that only proteins existing abundantly in the cytoplasm, such as tubulins and Hsp70, were identified as AF-1 domain-associated proteins. It is possible that signaling molecules, which are not expressed abundantly enough to be detected using our method, interact with the AF-1 or AF-2 domain at the plasma membrane and play an important role. Further improvement in our purification and identification method is necessary to characterize these molecules.

In conclusion, we have shown that the AF-1 domain of ER $\alpha$  interacts with microtubules at the plasma membrane, and Hsp70 outside the nucleus. We also demonstrated that the AF-2 domain of ER $\alpha$  is phosphorylated at the plasma membrane. We hypothesize that ER $\alpha$  forms a complex with microtubule-associated signaling molecules and phosphotyrosine-dependent AF-2-associated molecules. However, the whole view of the ER $\alpha$  complex is still unclear. To understand the pathological function of ER $\alpha$  in breast cancers, further investigation is required. This will lead to further improvement in breast cancer therapy and also bring about a deeper understanding of the physiological processes in which nuclear receptors are involved.

*Acknowledgements:* We thank Dr. I. Kitabayashi (Molecular Oncology Division, National Cancer Center Research Institute) for mass spectrometry analysis. K.A. is an awardee of the Research Resident Fellowship from the Foundation for Promoting Cancer Research (Japan) for the third Term Comprehensive 10-Year Strategy for Cancer Control. This study was supported by the Program for the Promotion of Fundamental Studies in the Health Science of Pharmaceuticals and Medical Devices Agency (PMDA).

## References

- [1] Evans, R.M. (1988) *Science* 240, 889–895.
- [2] Mangelsdorf, D.J. et al. (1995) *Cell* 83, 835–839.
- [3] Tora, L., White, J., Brou, C., Tasset, D., Webster, N., Scheer, E. and Chambon, P. (1989) *Cell* 59, 477–487.
- [4] Endoh, H. et al. (1999) *Mol. Cell. Biol.* 19, 5363–5372.
- [5] Rachez, C. et al. (1999) *Nature* 398, 824–828.
- [6] Watanabe, M. et al. (2001) *EMBO J.* 20, 1341–1352.
- [7] Belandia, B., Orford, R.L., Hurst, H.C. and Parker, M.G. (2002) *EMBO J.* 21, 4094–4103.
- [8] Yanagisawa, J. et al. (2002) *Mol. Cell.* 9, 553–562.
- [9] Belandia, B. and Parker, M.G. (2003) *Cell* 114, 277–280.
- [10] Fernandes, I. et al. (2003) *Mol. Cell.* 11, 139–150.
- [11] Ylikomi, T., Bocquel, M.T., Berry, M., Gronemeyer, H. and Chambon, P. (1992) *EMBO J.* 11, 3681–3694.
- [12] Haynes, M.P., Sinha, D., Russell, K.S., Collinge, M., Fulton, D., Morales-Ruiz, M., Sessa, W.C. and Bender, J.R. (2000) *Circ. Res.* 87, 677–682.
- [13] Simoncini, T., Hafezi-Moghadam, A., Brazil, D.P., Ley, K., Chin, W.W. and Liao, J.K. (2000) *Nature* 407, 538–541.
- [14] Kousteni, S. et al. (2001) *Cell* 104, 719–730.
- [15] Migliaccio, A. et al. (2000) *EMBO J.* 19, 5406–5417.
- [16] Song, R.X., McPherson, R.A., Adam, L., Bao, Y., Shupnik, M., Kumar, R. and Santen, R.J. (2002) *Mol. Endocrinol.* 16, 116–127.
- [17] Hochstrasser, D.F., Patchornik, A. and Merrill, C.R. (1988) *Anal. Biochem.* 173, 412–423.
- [18] Osharov, N. and Levitzki, A. (1994) *Eur. J. Biochem.* 225, 1047–1053.
- [19] Luttrell, D.K. et al. (1994) *Proc. Natl. Acad. Sci. USA* 91, 83–87.
- [20] Muthuswamy, S.K. and Muller, W.J. (1995) *Oncogene* 11, 271–279.
- [21] van Horck, F.P., Ahmadian, M.R., Haeuster, L.C., Moolenaar, W.H. and Kranenburg, O. (2001) *J. Biol. Chem.* 276, 4948–4956.
- [22] Chen, Z., Otto, J.C., Bergo, M.O., Young, S.G. and Casey, P.J. (2000) *J. Biol. Chem.* 275, 41251–41257.
- [23] Wang, T.H., Popp, D.M., Wang, H.S., Saitoh, M., Mural, J.G., Henley, D.C., Ichijo, H. and Wimalasena, J. (1999) *J. Biol. Chem.* 274, 8208–8216.
- [24] Connell, P., Ballinger, C.A., Jiang, J., Wu, Y., Thompson, L.J., Hohfeld, J. and Patterson, C. (2001) *Nat. Cell. Biol.* 3, 93–96.
- [25] Meacham, G.C., Patterson, C., Zhang, W., Younger, J.M. and Cyr, D.M. (2001) *Nat. Cell. Biol.* 3, 100–105.
- [26] Reid, G. et al. (2003) *Mol. Cell.* 11, 695–707.

# Hippocampal Synaptic Modulation by the Phosphotyrosine Adapter Protein ShcC/N-Shc via Interaction with the NMDA Receptor

Yoshiaki Miyamoto,<sup>1</sup> Ling Chen,<sup>2</sup> Masahiro Sato,<sup>1</sup> Masahiro Sokabe,<sup>2,3</sup> Toshitaka Nabeshima,<sup>4</sup> Tony Pawson,<sup>5</sup> Ryuichi Sakai,<sup>6</sup> and Nozomu Mori<sup>1,7</sup>

<sup>1</sup>Department of Molecular Genetics, National Institute for Longevity Sciences, Oobu 474-8522, Japan, <sup>2</sup>Cell Mechanosensing Project, International Cooperative Research Project–Japan Science and Technology Agency, and Departments of <sup>3</sup>Physiology and <sup>4</sup>Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Japan, <sup>5</sup>Department of Molecular and Medical Genetics, University of Toronto, Toronto, Ontario M5S 1A8, Canada, <sup>6</sup>Growth Factor Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan, and <sup>7</sup>Department of Anatomy and Neurobiology, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan

N-Shc (neural Shc) (also ShcC), an adapter protein possessing two phosphotyrosine binding motifs [PTB (phosphotyrosine binding) and SH2 (Src homology 2) domains], is predominantly expressed in mature neurons of the CNS and transmits neurotrophin signals from the TrkB receptor to the Ras/mitogen-activated protein kinase (MAPK) pathway, leading to cellular growth, differentiation, or survival. Here, we demonstrate a novel role of ShcC, the modulation of NMDA receptor function in the hippocampus, using *ShcC* gene-deficient mice. In behavioral analyses such as the Morris water maze, contextual fear conditioning, and novel object recognition tasks, ShcC mutant mice exhibited superior ability in hippocampus-dependent spatial and nonspatial learning and memory. Consistent with this finding, electrophysiological analyses revealed that hippocampal long-term potentiation in ShcC mutant mice was significantly enhanced, with no alteration of presynaptic function, and the effect of an NMDA receptor antagonist on its expression in the mutant mice was notably attenuated. The tyrosine phosphorylation of NMDA receptor subunits NR2A and NR2B was also increased, suggesting that ShcC mutant mice have enhanced NMDA receptor function in the hippocampus. These results indicate that ShcC not only mediates TrkB-Ras/MAPK signaling but also is involved in the regulation of NMDA receptor function in the hippocampus via interaction with phosphotyrosine residues on the receptor subunits and serves as a modulator of hippocampal synaptic plasticity underlying learning and memory.

**Key words:** ShcC/N-Shc; phosphotyrosine adapter protein; learning and memory; long-term potentiation; hippocampus; NMDA receptor

## Introduction

Long-term potentiation (LTP) in the hippocampus, a well characterized form of activity-dependent synaptic plasticity, serves as a major cellular mechanism of learning and memory (Bliss and Collingridge, 1993; Malenka and Nicoll, 1999). The NMDA and AMPA types of glutamate receptors (GluRs) play critical roles in the induction of hippocampal LTP (Tsien et al., 1996; Zamanillo et al., 1999). In addition to the primary importance of the glutamate receptors, it has been reported that neurotrophins, particularly brain-derived neurotrophic factor (BDNF), modulate the maintenance of hippocampal LTP through the activation of TrkB

receptor tyrosine kinases (Poo, 2001; Lu, 2003). Also, a variety of intracellular signaling cascades, including the Ras/mitogen-activated protein kinase (MAPK) pathway, are reported to influence LTP formation (Ohno et al., 2001; Silva, 2003).

The BDNF-activated TrkB receptors recruit various adapter proteins such as Shc, Frs-2, and phospholipase-C $\gamma$  (PLC $\gamma$ ). The adapter proteins are tyrosine phosphorylated by the activated TrkB receptors and determine the flow of downstream intracellular signaling cascades to cellular growth, differentiation, or survival. Binding of Shc or Frs-2 leads to the activation of Ras/MAPK and PI3K (phosphoinositide-3 kinase)/Akt pathways, whereas binding of PLC $\gamma$  stimulates the release of intracellular Ca<sup>2+</sup> via inositol 1,4,5-trisphosphate (IP3) and thereby activates the Ca<sup>2+</sup>-calmodulin-dependent kinase IV (CaMKIV) pathway (Kaplan and Miller, 2000; Patapoutian and Reichardt, 2001). Therefore, it is hypothesized that TrkB-Ras/MAPK signaling plays a role in the hippocampal LTP underlying learning and memory (Adams and Sweatt, 2002; Ying et al., 2002).

The Shc family consists of ShcA/Shc (p66, p52, and p46 isoforms), ShcB/Sck (p68), and ShcC/neural Shc (N-Shc) (p69 and p55), and possesses two modular regions that bind to phosphorylated tyrosine-containing peptide motifs: a PTB (phosphoty-

Received March 3, 2004; revised Dec. 30, 2004; accepted Jan. 3, 2005.

The initial part of this work was supported by the program "Protecting the Brain" of the Core Research for Evolutional Science and Technology—Japan Science and Technology Agency, and later, in part, by a Virtual Research Institute of Aging fund of Nippon Boehringer Ingelheim, the Uehara Memorial Research Fund, Funds for Comprehensive Research on Aging and Health from Ministry of Health, Labor, and Welfare, and grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. We thank Dr. T. Nakamura for valuable advice and I. Nakano and Y. Kadokawa for technical assistance and laboratory maintenance.

Correspondence should be addressed to Dr. Nozomu Mori, Department of Anatomy and Neurobiology, Nagasaki University School of Medicine, 1-12-4 Sakamoto, Nagasaki 852-8523, Japan. E-mail: morinosm@net.nagasaki-u.ac.jp.

DOI:10.1523/JNEUROSCI.3030-04.2005

Copyright © 2005 Society for Neuroscience 0270-6474/05/251826-10\$15.00/0

rosine binding) domain and an SH2 (Src homology 2) domain. All of the Shc family members serve to link a number of receptor tyrosine kinases with multiple intracellular signaling cascades. ShcA is widely expressed in most tissues, whereas both ShcB and ShcC are predominantly expressed in the nervous system (Cattaneo and Pelicci, 1998; Ravichandran, 2001). The brain-enriched ShcC would be in a good position to modulate the hippocampal LTP via regulation of TrkB-Ras/MAPK signaling, because it has been implicated in the BDNF-TrkB signaling toward the Ras/MAPK pathway in cultured cells (Nakamura et al., 1998; Liu and Meakin, 2002).

Recent studies revealed that the so-called “Shc site” of the TrkB receptor (Tyr<sup>515</sup>) was not relevant to the hippocampal LTP, because mice with a targeted point mutation of the TrkB–Shc site showed apparently no significant change in LTP formation (Korte et al., 2000; Minichiello et al., 2002). These findings are in contrast to the aforementioned hypothesis pointing to a role for TrkB-Ras/MAPK signaling in the hippocampal LTP. Accordingly, in the present study, we attempted to clarify whether the phosphotyrosine adapter protein ShcC, which binds the TrkB–Shc site leading to the Ras/MAPK pathway, is involved in hippocampal functions, using ShcC gene-deficient mice. Based on the results presented herein, we propose a novel role for ShcC in hippocampal synaptic plasticity, as evidenced by the enhancement of hippocampal LTP and hippocampus-dependent learning and memory in ShcC mutant mice.

## Materials and Methods

**Animals.** Mice lacking ShcC were generated by Sakai et al. (2000). The homozygous mutant mice ( $-/-$ ; 3 months of age) and the littermate 2 wild-type mice ( $+/+$ ; 3 months of age) were obtained by crossing F2 heterozygous mutant mice ( $+/-$ ). The genotypes of mice were determined by Southern blot analyses of tail DNA. C57BL/6 mice (Nihon SLC, Hamamatsu, Japan) were used for biochemical analyses of the Shc family members. The mice were housed in plastic cages and were kept in a regulated environment ( $24 \pm 1^\circ\text{C}$ ;  $50 \pm 5\%$  humidity), with a 12 h light/dark cycle (lights on at 9:00 A.M.). Food and tap water were available *ad libitum*. All of the experiments were performed in accordance with the Guidelines for Animal Experiments of the Nagoya University School of Medicine. The procedures involving animals and their care were conducted in conformity with the international guidelines *Principles of Laboratory Animal Care* (National Institutes of Health publication 85-23, revised 1985).

**Plasmids and antibodies.** Plasmids encoding cDNAs of mouse p52-ShcA, p68-ShcB, and p55-ShcC were as described previously (Kojima et al., 2001) and were epitope-tagged with T7 at the N terminus. Antibodies against ShcA (catalog #S68020) and ShcC (S55720) were obtained from Transduction Laboratories (San Diego, CA). Antibody against ShcB was prepared as described previously (Sakai et al., 2000). Anti-phosphotyrosine antibody (catalog #05-321) was purchased from Upstate Biotechnology (Charlottesville, VA). Antibodies against NR1 (catalog #sc-9058), NR2A (catalog #sc-9056), NR2B (catalog #sc-9057), postsynaptic density 95 (PSD95) (catalog #sc-6926), Src (catalog #sc-5266), Fyn (catalog #sc-434), and the Src family (catalog #sc-18) were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-Src family (Tyr<sup>418</sup>) antibody (catalog #44-660) was purchased from Biosource (Camarillo, CA).

**Northern blot analysis.** Total RNAs were isolated using TRIzol reagents (Invitrogen, Carlsbad, CA). Isolated total RNAs (20  $\mu\text{g}$ ) were electrophoresed on a formalin-agarose gel and blotted onto a positively charged nylon membrane. Specific cDNA probes for the Shc family members were made by Megaprime DNA labeling systems and [ $\alpha$ -<sup>32</sup>P]dCTP (Amersham Biosciences, Piscataway, NJ) and purified with NucTrap Probe Purification Columns (Stratagene, La Jolla, CA). Membranes were hybridized with the <sup>32</sup>P-labeled cDNA probes as described previously (Nakamura et al., 1998).

**In situ hybridization analysis.** Mouse brain sections (15  $\mu\text{m}$ ) were cut

on a cryostat, thaw-mounted on poly-L-lysine-coated slides, and stored at  $-80^\circ\text{C}$  until use. The frozen brain sections were brought to room temperature and air-dried. The sections were postfixed with 4% paraformaldehyde in 0.1 M phosphate buffer, acetylated with 0.25% acetic anhydride in 0.1 M triethanolamine, and dehydrated through an ascending series of ethanol concentrations. To prepare antisense and sense cRNA probes, the plasmids encoding cDNA of ShcA, ShcB, or ShcC were linearized by cutting at a single site (antisense, EcoRI; sense, HindIII). *In vitro* transcription was performed using RNA polymerase (antisense, T7 RNA polymerase; sense, SP6 RNA polymerase) and [ $\alpha$ -<sup>35</sup>S]UTP (ICN Biomedicals, Costa Mesa, CA). *In situ* hybridization with the <sup>35</sup>S-labeled cRNA probes was performed as described previously (Nakamura et al., 1998). The sections were counterstained with thionine and dehydrated. The images were captured by the HC-2000 video camera system (Fuji Photo Film, Tokyo, Japan) and reconstructed using computer software.

**Western blot analysis and immunoprecipitation assay.** Mouse brains were homogenized in a lysis buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 10 mM NaF, 1 mM sodium orthovanadate, 1% Triton X-100, 0.5% sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, and protease inhibitor mixture (Complete; Roche, Mannheim, Germany)] or a modified lysis buffer containing 0.1% SDS for immunoprecipitation assays. For Western blot analysis, total proteins (10  $\mu\text{g}$ ) were separated by SDS-PAGE and blotted onto a polyvinylidene difluoride (PVDF) membrane. For immunoprecipitation assays, total proteins (500  $\mu\text{g}$ ) were incubated with an appropriate antibody and then protein G-Sepharose was added and further incubated. The immunoprecipitates were recovered by centrifugation and resuspended in a sample buffer. The samples (10  $\mu\text{l}$ ) were separated by electrophoresis and blotted onto a PVDF membrane. The membranes were incubated with primary antibodies, and proteins were detected by HRP-conjugated secondary antibodies using the ECL detection kit (Amersham Biosciences).

**Histological analysis.** Mouse brains were perfused with 4% paraformaldehyde in PBS and removed. Sections (15  $\mu\text{m}$ ) were cut, mounted on slides, and stored at  $-80^\circ\text{C}$  until use. Nissl staining was done according to standard procedures. The images were captured with an HC-2000 video camera system. For immunohistochemical staining, the sections were permeabilized with 0.2% Triton X-100, blocked with 3% BSA, and incubated with antibody against microtubule-associated protein 2 (MAP2) (catalog #M1406; Sigma, St. Louis, MO). To detect specific signals for MAP2, the sections were incubated with Alexa Fluor 488-conjugated secondary antibody (catalog #A-11029; Molecular Probes, Eugene, OR). Fluorescence images were obtained with the confocal imaging system Micro Radiance (Bio-Rad Laboratories, Hercules, CA).

**Behavioral analysis.** To measure locomotor activity, a mouse was placed in a transparent acrylic cage with a black Plexiglas floor ( $45 \times 26 \times 40$  cm), and locomotion and rearing were measured for 60 min using infrared counters (Scanet SV-10; Toyo Sangyo, Toyama, Japan).

To measure nociceptive responses to electric footshock, a mouse was placed in a transparent Plexiglas cage with a grid floor for footshock ( $25 \times 30 \times 11$  cm) and an ascending footshock series (0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.08, 0.10, 0.13, 0.16, 0.20, 0.25, 0.30, 0.40, 0.50, and 0.60 mA for 0.5 s; 30 s interval) was delivered through an electric shock generator (NS-SG01; Neuroscience, Tokyo, Japan). The electric current needed to elicit first flinching, vocalizing, or jumping behavior was recorded as the footshock threshold.

For the Morris water maze task, a pool (120 cm in diameter) was prepared with white plastic, and the water temperature was maintained at  $20^\circ\text{C}$ . Swimming paths were analyzed by a computer system with a video camera (AXIS-90 Target/2; Neuroscience). In the hidden-platform test, the platform (7 cm in diameter) was submerged 1 cm below the water surface. Mice did not swim in the pool before training. Three starting positions were used pseudorandomly, and each mouse was trained with three trials per day for 6 d. After reaching the platform, the mouse was allowed to remain on it for 30 s. If the mouse did not find the platform within 60 s, the trial was terminated and the animal was put on the platform for 30 s. In the platform transfer test, the mouse swam for 60 s in the pool without the platform. In the visible-platform test, the black platform was located 1 cm above the water surface.


For the fear conditioning task, a mouse was placed in a training cage

(25 × 30 × 11 cm), which consisted of transparent Plexiglas with a grid floor for footshock, and the freezing response as the immobility time was measured for 2 min in the absence of sound and footshock (preconditioning) using Scanet SV-10AQ (Toyo Sangyo), which can measure automatically the immobility time by digital counters with infrared sensors. In the conditioning, the mouse was again placed in the cage, and the pretrial time of 2 min was followed by a 15 s tone stimulus (80 dB). During the last 5 s of the tone stimulus, a footshock of 0.8 mA was delivered through a shock generator (NS-SG01; Neuroscience). This procedure was repeated four times with 15 s intervals. In the pseudoconditioning, the mouse was exposed to the conditioning without footshock. For the contextual test 24 h after the conditioning, the mouse was placed back in the same cage in the absence of sound and footshock. For the cued test 24 h after the conditioning, the mouse was placed in a novel cage (45 × 26 × 40 cm), which was made of a transparent acrylic cage with a black Plexiglas floor, in the presence of a continuous tone stimulus.

For the novel object recognition task, a mouse was habituated to a black plastic cage (30 × 30 × 50 cm) for 3 d. In the training, two novel objects were placed in the cage, and the mouse was allowed to explore freely for 5 min. Time spent exploring each object was recorded manually. In retentions 2 or 24 h after the training, the mouse was placed back in the same cage, in which one of the familiar objects used in the training was replaced by a novel object, and allowed to explore for 5 min. Exploratory preference, a ratio of time spent exploring any one of the two objects (training) or the novel one (retention) over the total time spent exploring both objects, was used to measure recognition memory.

**Electrophysiological analysis.** Mouse brains were removed and kept in artificial CSF (ACSF) (in mM: 128 NaCl, 1.7 KCl, 26 NaHCO<sub>3</sub>, 1.2 KH<sub>2</sub>PO<sub>4</sub>, 2.4 CaCl<sub>2</sub>, 1.3 MgSO<sub>4</sub>, and 10 glucose). ACSF was saturated with a mixture of 95% O<sub>2</sub>/5% CO<sub>2</sub>. Slices of the hippocampus (350 μm) were prepared using a microslicer (DTK-1500; Dosaka EM, Kyoto, Japan) and placed for 1 h in an incubation chamber filled with ACSF. The slices were stained with a voltage-sensitive dye, RH 482 (0.1 mg/ml; Nippon Kanko-Shikiso Kenkyusho, Okayama, Japan). The stained slices were transferred to a recording chamber mounted on an inverted microscope (IMT-2; Olympus, Tokyo, Japan). The recording chamber was continuously perfused with ACSF. The optical recording system (HR Deltaron 1700; Fuji Photo Film) consists of an area sensor with 128 × 128 photodiodes and a data-processing unit. Each photodiode receives optical signals from a 25 × 25 μm sample area, thus creating a 3.3 × 3.3 mm recording field. For optical recordings, an ACSF-filled glass electrode was placed in the hippocampal CA3 area. Schaffer collateral afferents were then stimulated with 300 μA/200 μs pulses, and a test stimulus was delivered at 0.06 Hz by a stimulator (SEN-3301; Nihon Kohden, Tokyo, Japan). In each trial, background signals were recorded for 10 ms before the electrical stimulus and stored as a reference image. Images after the stimulus were recorded at 0.6 ms/frame, and the difference signals from the reference image were digitized into 8 bit signals. The digitized signals were then amplified 400 times. To improve the signal-to-noise ratio, 16 trial images were averaged into a single image. A total of 150 sequential images, corresponding to a ~90 ms recording time, were collected from one experiment. The level of neuronal activities was indicated with pseudocolor (256 colors). To analyze the time course of activities in a given sample area, data from each pixel were stored, retrieved, and plotted as a function of time using Origin 5.0 (OriginLab, Northampton, MA).

**In vitro kinase assay.** Immunoprecipitates from the hippocampus were suspended in Src kinase reaction buffer (in mM: 100 Tris-HCl, pH 7.5, 125 MgCl<sub>2</sub>, 25 MnCl<sub>2</sub>, 2 EGTA, 0.2 sodium orthovanadate, and 2 dithio-



**Figure 1.** Expression profiles of Shc family members in the brain. **A**, mRNA expression of Shc family members during brain development. Total RNAs from whole brain in various developmental stages were examined by Northern blot analysis. **B**, Protein expression of Shc family members during brain development. Protein extracts from whole brain in various developmental stages were examined by Western blot analysis. **C**, mRNA expression of ShcB and ShcC in the mature brain [10 weeks of age (10W)]. mRNAs were examined by *in situ* hybridization analysis. Scale bar, 1 mm. **D**, Protein expression of ShcB and ShcC in various regions of the mature brain (10W). Protein extracts from various regions of the brain were examined by Western blot analysis. E12.5 and E15.5, Embryonic days 12.5 and 15.5; OB, olfactory bulb; CC, cerebral cortex; HIP, hippocampus; STR, striatum; THA, thalamus; CB, cerebellum; MB, midbrain.

threitol). The kinase assay was performed using a Src kinase kit (catalog #17-131; Upstate Biotechnology).


**Pharmacological treatment of tissue slices.** The hippocampi were quickly dissected and sliced in two directions at a thickness of 350 μm using a McIlwain tissue chopper (Mickle Laboratory Engineering, Gomshall, UK). The hippocampal slices were incubated at 37°C for 1 h in the netwell chamber (Corning, Corning, NY) filled with ACSF, which was continuously saturated with a mixture of 95% O<sub>2</sub>/5% CO<sub>2</sub>, and then exposed to ACSF in the presence of glutamate (100 μM), glycine (10 μM), and spermidine (1 mM) for 5 min. After a wash in ice-cold ACSF, the slices were homogenized in the modified lysis buffer.

**Statistical analysis.** All of the data were expressed as mean ± SEM. Statistical differences between the mutant mice and the wild-type mice were determined with Student's *t* comparison test. In the analysis of the visible or hidden test in the Morris water maze test, statistical differences were determined by an ANOVA with repeated measures. In the analysis of the transfer test in the Morris water maze, fear conditioning, and novel object recognition tasks, statistical differences among values for individual groups were determined by ANOVA, followed by the Student–Newman–Keuls multiple comparisons test when *F* ratios were significant (*p* < 0.05).

## Results

### ShcC/N-Shc, a major phosphotyrosine adapter protein in the mature hippocampus

The gene expression of Shc-related phosphotyrosine adapter proteins was under dynamic regulation during the mammalian brain development (Fig. 1A, B). The expression level of ShcA, both the mRNA and protein, decreased during perinatal development and almost disappeared by 10 weeks of age. In contrast, that of ShcC increased gradually during postnatal development, with a peak at approximately postnatal day 7 (P7) to P14. However, ShcB mRNA levels remained low and invariable at all of the developmental stages, whereas its protein levels existed relatively high at P7 and P14. *In situ* hybridization analysis of young adults at 10



**Figure 2.** Hippocampal morphology in ShcC mutant mice. *A*, Protein expression of ShcB and ShcC in ShcC mutant mice [10 weeks of age (10W)]. Protein extracts from the cerebral cortex (CC) and hippocampus (HIP) of ShcB and ShcC mutant mice were examined by Western blot analysis. *B*, Nissl staining in the hippocampus of ShcC mutant mice (10W). DG, Dentate gyrus. Scale bar, 200  $\mu$ m.

weeks of age revealed that ShcC mRNA was highly expressed in the cerebral cortex, hippocampus, and thalamus (Fig. 1C). In contrast, the expression of ShcB mRNA was rather ubiquitous (Fig. 1C). The regional expression of ShcC protein correlated with the mRNA data, whereas that of ShcB protein was different from mRNA and showed some deviations (i.e., a few high expressions in the hippocampus, thalamus, and midbrain) (Fig. 1D). The expression of ShcA was negligible in the various regions of the brain at 10 weeks of age (data not shown). These findings indicate that ShcC is the primary phosphotyrosine adapter protein among the Shc family members in the hippocampus of adult animals.

#### Histological appearance of hippocampal neurons in ShcC mutant mice

ShcC mutant mice exhibited a complete loss of ShcC protein, but the expression of ShcB was unaffected in most regions of the brain at 10 weeks of age (Fig. 2A, cerebral cortex and hippocampus). Neuroanatomically, the hippocampus of ShcC mutant mice revealed no gross structural abnormalities on Nissl staining compared with that of wild-type mice (Fig. 2B). MAP2 immunostaining for the dendrites of neurons in the hippocampal CA1 area of the mutant mice gave a pattern indistinguishable from that in wild-type mice (data not shown). Thus, the deficiency of ShcC did not significantly alter the hippocampal morphology in the mature brain.

#### Enhancement of hippocampus-dependent learning and memory in ShcC mutant mice


To investigate whether a deficiency of ShcC affects neuronal functions of the mature brain, we examined the performance of ShcC mutant mice in several behavioral paradigms. We first

tested motor coordination and nociceptive response. The motility in a novel environment was measured for both horizontal (locomotion) and vertical (rearing) activities. Neither locomotion nor rearing during a 60 min observation period differed significantly between the wild-type mice (locomotion,  $13,122.2 \pm 1197.8$  counts; rearing,  $70.7 \pm 13.8$  counts) and ShcC mutant mice (locomotion,  $13,355.0 \pm 1405.0$  counts; rearing,  $81.8 \pm 14.1$  counts). Furthermore, no aberrant nociceptive responses to electric footshocks were observed in the ShcC mutant mice: the footshock threshold in the mutant mice (flinching,  $0.045 \pm 0.002$  mA; vocalizing,  $0.233 \pm 0.027$  mA; jumping,  $0.425 \pm 0.031$  mA) was the same as that in wild-type mice (flinching,  $0.045 \pm 0.004$  mA; vocalizing,  $0.228 \pm 0.015$  mA; jumping,  $0.400 \pm 0.046$  mA). These results indicate no apparent abnormalities in either motor or sensory neuronal systems in the ShcC mutant mice, consistent with previous observations (Sakai et al., 2000).

We next tested spatial and nonspatial learning and memory in ShcC mutant mice using the paradigms of the Morris water maze, fear conditioning, and novel object recognition tasks. In the Morris water maze task, both the wild-type and ShcC mutant mice managed to learn the visible-platform test, but the escape latency to the platform was shorter for the mutant mice (ANOVA with repeated measures;  $F_{(1,22)} = 4.446$ ;  $p = 0.0010$ ) (Fig. 3Aa). In the hidden-platform test, which requires the activation of the NMDA receptors in the hippocampus (Morris et al., 1982; Tsien et al., 1996), ShcC mutant mice required less time to reach the platform than wild-type mice (ANOVA with repeated measures;  $F_{(1,34)} = 3.689$ ;  $p = 0.0034$ ) (Fig. 3Ab). Swimming speeds of the wild-type and ShcC mutant mice in the visible- and hidden-platform tests were essentially the same (swimming speed on the first day of the hidden-platform test; wild-type mice,  $17.9 \pm 1.2$  cm/s; ShcC mutant mice,  $18.6 \pm 1.1$  cm/s). Moreover, in the platform transfer test conducted after the hidden-platform test, the ShcC mutant mice exhibited greater preference for the trained quadrant than the wild-type mice (Fig. 3Ac).

We tested for associative memory in the contextual and cued fear conditioning tasks. The former is hippocampus dependent, whereas the latter is hippocampus independent (Phillips and LeDoux, 1992). Both types of fear conditioning task also require the activation of the NMDA receptors (Davis et al., 1987; Kim et al., 1992). The contextual and cued fear conditioning tasks were measured 24 h after an aversive event (footshock) using two separate sets of genotype groups. The freezing response before the footshock (preconditioning) did not differ between the wild-type and ShcC mutant mice (Fig. 3B). In the contextual fear conditioning test, the freezing response 24 h after the footshock in both the wild-type and ShcC mutant mice significantly increased compared with the preconditioning and pseudoconditioning groups, respectively, with the mutant mice exhibiting a much stronger response than wild-type mice (Fig. 3B). In contrast, in the cued fear conditioning test, there was no significant difference in the freezing response 24 h after the footshock between the wild-type mice ( $62.6 \pm 5.1\%$ ) and ShcC mutant mice ( $64.6 \pm 3.3\%$ ).

To examine visual recognition memory in ShcC mutant mice, we used a novel object recognition task, in which the activation of the NMDA receptors in the hippocampus is essential for the formation of recognition memory (Rampon et al., 2000). We used a 5 min training protocol to assess the enhancement of learning and memory. There was no difference in exploratory preference during the training between the wild-type and ShcC mutant mice (Fig. 3C), indicating that the two groups essentially had the same levels of curiosity and/or motivation to explore the two objects.




**Figure 3.** Hippocampus-dependent learning and memory in ShcC mutant mice. *A*, Morris water maze task. Escape latency in the visible (*a*)- and hidden (*b*)-platform tests. *c*, The time spent in each quadrant in the transfer test 24 h after the hidden-platform test. The time spent in the trained quadrant was significantly longer than that in any other quadrants in both the wild-type and ShcC mutant mice ( $p < 0.05$ ; Student–Newman–Keuls multiple comparisons test). The dotted line represents performance by chance (15 s). *B*, Contextual fear conditioning test. The freezing response was measured for 2 min 24 h after the conditioning [FS (footshock)] or pseudoconditioning (Non-FS). *C*, Novel object recognition test. The time spent exploring two objects was measured for 5 min during training and retention 2 or 24 h after the training. The dotted line represents performance by chance (50%). Data represent mean  $\pm$  SEM ( $n = 8–18$ ). \* $p < 0.05$  and \*\* $p < 0.01$  versus corresponding wild type (+/+). # $p < 0.05$  and ## $p < 0.01$  versus corresponding non-FS or training value in wild type (+/+).

In 2 and 24 h retention, however, ShcC mutant mice exhibited greater preference toward the novel object than wild-type mice (Fig. 3*C*).

Overall, these findings in the three different paradigms suggest that hippocampus-dependent spatial and nonspatial learning and memory is enhanced in the ShcC mutant mice, and this enhancement reflects neither increased motor activity nor altered nociceptive sensitivity.

#### Enhancement of hippocampal LTP in ShcC mutant mice

To investigate the synaptic properties in the hippocampus of ShcC mutant mice, we performed electrophysiological analyses using hippocampal slices. We used a high-speed optical recording technique in the hippocampal CA1 area by stimulating Schaffer collateral afferents from the CA3 area. With this technique, the optical signals evoked in the stratum radiatum of the CA1 area were broken down into two distinct elements, an initial spike-like component and an immediately following slow component, which could be separated by a notch in the control (Fig. 4*Aa*, arrow). These components represent the presynaptic fiber volley (PSFV) and EPSP, respectively, because the spike-like component left in  $Ca^{2+}$ -free medium (Fig. 4*Ab*) is eliminated by tetrodotoxin (TTX; 1  $\mu$ M) (Fig. 4*Ad*) and the slow component is



**Figure 4.** Hippocampal synaptic transmission and LTP in ShcC mutant mice. *A*, Optical signals in the stratum radiatum of the hippocampal (HIP) CA1 area. Representative traces of optical signal in response to an electrical stimulus of the Schaffer collateral fibers are shown. The control signal (*a*) is composed of PSFV (arrow) and EPSP; the former could be separated by treatment with  $Ca^{2+}$ -free medium (*b*) or AP-5 (50  $\mu$ M)/CNOX (10  $\mu$ M) (*c*) and eliminated by treatment with TTX (1  $\mu$ M) (*d*). *B*, Amplitude of PSFV versus stimulus intensity. *C*, Amplitude of EPSP versus stimulus intensity. The input–output relationship of PSFV or EPSP is plotted against stimulus intensity at the Schaffer collateral–CA1 synapses (5 slices from 4 wild-type mice; 5 slices from 5 ShcC mutant mice). *D*, Paired-pulse facilitation (PPF). The data represent the facilitation of the second EPSP ( $S_2$ ) relative to the first EPSP ( $S_1$ ). Traces are the synaptic responses evoked by paired-pulse stimulation (interval, 25 ms) (4 slices from 3 wild-type mice; 4 slices from 3 ShcC mutant mice). *E*, Hippocampal LTP. Each point represents the mean  $\pm$  SEM EPSP normalized to the baseline EPSP, which was the mean of EPSP for 20–30 min (7 slices from 4 wild-type mice; 7 slices from 4 ShcC mutant mice). Tetanic stimulation induced LTP at 90 min in the wild-type mice (121.2  $\pm$  5.0%) and ShcC mutant mice (136.8  $\pm$  3.4%;  $p < 0.05$ ). *F*, Treatment with NMDA receptor antagonist AP-5. Each point represents the normalized mean  $\pm$  SEM of EPSP (25  $\mu$ M) for 5–35 min (4 slices from 4 wild-type mice; 6 slices from 4 ShcC mutant mice). Tetanic stimulation with AP-5 treatment failed to induce LTP in the wild-type mice (103.5  $\pm$  7.0% at 90 min), and induced LTP in ShcC mutant mice (120.1  $\pm$  6.7% at 90 min;  $p < 0.05$ ). *G*, Dose–effect of AP-5 on LTP expression. Each point represents the normalized mean  $\pm$  SEM EPSP at 60 min after the tetanic stimulation in the presence of different concentrations of AP-5 (4 slices from 4 wild-type mice; 6 slices from 4 ShcC mutant mice) (EC<sub>50</sub>: wild-type mice, 15.2  $\mu$ M; ShcC mutant mice, 26.6  $\mu$ M).


blocked by D-2-amino-5-phosphonovaleric acid (AP-5; 50  $\mu$ M)/6-cyano-7-nitroquinoline-2,3-dione (CNQX; 10  $\mu$ M), competitive NMDA and AMPA receptor antagonists (Fig. 4A).

Initial experiments were designed to examine the input–output relationship of synaptic transmission by measuring two distinct components for a range of stimulus intensities. The amplitude of PSFV in the wild-type and ShcC mutant mice was almost the same (Fig. 4B), indicating that presynaptic properties were not altered in the mutant mice. There was no difference in the amplitude of EPSP between the wild-type and ShcC mutant mice (Fig. 4C), indicating that basal synaptic transmission remains normal in the mutant mice. Similarly, paired-pulse facilitation, which is a short-term enhancement of synaptic efficacy in response to a closely spaced second stimulus and reflects the probability of neurotransmitter release from afferent neurons, differed little between the wild-type and ShcC mutant mice (Fig. 4D). These results suggest that synaptic transmission does not deteriorate at the hippocampal Schaffer collateral-CA1 synapses in the ShcC mutant mice.

The LTP in the hippocampal CA1 area, a typical form of synaptic plasticity, is known to involve the activation of the NMDA receptors in its induction. We next examined the synaptic plasticity at hippocampal CA1 synapses using a high-frequency conditioning, tetanic stimulation (100 Hz; 1 s) to induce LTP. There was a marked difference in the expression of hippocampal LTP between the wild-type and ShcC mutant mice (Fig. 4E). The early phase of LTP in ShcC mutant mice was consistently enhanced during observation up to 60 min after the tetanic stimulation (wild-type mice,  $121.2 \pm 5.0\%$ ; ShcC mutant mice,  $136.8 \pm 3.4\%$ ;  $p < 0.05$ ) (Fig. 4E, EPSP at 90 min). The treatment with AP-5 (25  $\mu$ M) before the tetanic stimulation in wild-type mice completely blocked the expression of LTP, whereas that in ShcC mutant mice induced LTP (EPSP at 90 min) (wild-type mice,  $103.5 \pm 7.0\%$ ; ShcC mutant mice,  $120.1 \pm 6.7\%$ ;  $p < 0.05$ ) (Fig. 4F). As shown in Figure 4G, AP-5 dose-dependently inhibited the expression of LTP in both the wild-type and ShcC mutant mice, but with different  $EC_{50}$  values of AP-5 between the two groups (wild-type mice, 15.2  $\mu$ M; ShcC mutant mice, 26.6  $\mu$ M). These results suggest that the enhancement of hippocampal LTP in ShcC mutant mice would arise from the functional alteration of postsynaptic NMDA receptors in the hippocampal CA1 area, because presynaptic function is normal in this area.

#### Increased phosphorylation of the NMDA receptors in the hippocampus of ShcC mutant mice

The NMDA receptors are formed by NR1 (GluR $\zeta$ 1) and NR2A to NR2D (GluR $\epsilon$ 1 to GluR $\epsilon$ 4) subunits (Hollmann and Heinemann, 1994; Nakanishi and Masu, 1994), and their activity is modulated by either the subunit composition of the receptor (Kutsuwada et al., 1992; Monyer et al., 1994) or phosphorylation of the subunits (Wang and Salter, 1994; Yu et al., 1997). To investigate NMDA receptor activity in the hippocampus of ShcC mutant mice, we examined the expression and phosphorylation levels of the receptor subunits. There was no difference in the expression level of the NR2A, NR2B, or NR1 subunit in the hippocampus between the wild-type and ShcC mutant mice (Fig. 5A). The expression level of PSD95, which regulates the signaling by the NMDA receptors, was the same in ShcC mutant mice as in wild-type mice (Fig. 5A). However, the tyrosine phosphorylation level of NR2A or NR2B in ShcC mutant mice showed a significant increase compared with that in wild-type mice (Fig. 5A). These findings suggest that the basal function of the NMDA receptors in



**Figure 5.** Phosphorylation of the NMDA receptors and kinase activity of the Src family in the hippocampus of ShcC mutant mice. **A**, Expression and tyrosine phosphorylation of the NR2A and NR2B subunits. The whole lysates of the hippocampus (HIP) were immunoblotted with anti-NR2A, -NR2B, -NR1, or -PSD95 antibody. To dissociate the NMDA receptor complex, hippocampal lysates with a modified lysis buffer were boiled for 5 min. The immunoprecipitates (IP) obtained with anti-NR2A or -NR2B antibody were immunoblotted with anti-phosphotyrosine (P-Tyr) antibody. **B**, Tyrosine phosphorylation at the activation site of Src and Fyn. The immunoprecipitates prepared with anti-Src or -Fyn antibody were immunoblotted with anti-phospho-Src (P-Src) family antibody. **C**, Kinase activity of the Src family *in vitro*. The immunoprecipitates obtained with anti-Src family antibody were subjected to an *in vitro* Src kinase assay. Data represent mean  $\pm$  SEM ( $n = 4$ ). \* $p < 0.05$  and \*\* $p < 0.01$  versus corresponding wild type (+/+).

the hippocampus of ShcC mutant mice is enhanced by the hyperphosphorylation at tyrosine residues of the receptor subunits.

Because the tyrosine phosphorylation of subunits NR2A and NR2B of the NMDA receptors is known to be modulated by the

Src family of cytoplasmic tyrosine kinases, including Src and Fyn (Hisatsune et al., 1999; Nakazawa et al., 2001), we tested the kinase activity of this family in the hippocampus of ShcC mutant mice. However, there was no notable difference in the tyrosine phosphorylation level at the activation site of Src or Fyn between the wild-type and ShcC mutant mice (Fig. 5B). Moreover, the kinase activity of the Src family in the mutant mice was similar to that in wild-type mice (Fig. 5C). These results indicate that increased tyrosine phosphorylation of the NMDA receptors in the ShcC mutant mice is not attributable to the activation of Src and Fyn.

#### Interaction of ShcC/N-Shc with the NMDA receptors and the Src family in the hippocampus


To clarify the regulatory mechanism of ShcC in NMDA receptor function involved in hippocampal synaptic plasticity, we investigated whether ShcC interacts with the NMDA receptors and the Src family. In an immunoprecipitation assay using lysates prepared from the hippocampus of wild-type mice, the NR1 or NR2B subunit of the NMDA receptors coprecipitated greatly with ShcC compared with other Shc family members (Fig. 6A). Similarly, Src (or Fyn) also interacted with ShcC (Fig. 6A). To further test whether these interactions would be affected by the activation of excitatory synaptic transmission, we examined the interaction between ShcC and the NR2B subunit or the Src family under conditions of glutamate stimulation in hippocampal slices from wild-type mice. After a 5 min stimulation with glutamate (100  $\mu$ M) in the presence of glycine (10  $\mu$ M) and spermidine (1 mM), both endogenous coactivators for the NMDA receptors, the amount of NR2B subunit coimmunoprecipitated with ShcC increased significantly (Fig. 6B). In the same conditions, the interaction of Src (or Fyn) with ShcC also increased significantly (Fig. 6B). These findings indicate that ShcC binds to the NMDA receptors and also associates with Src and/or Fyn in the mature hippocampus, and the formation of this ternary complex is stimulated by the activation of the excitatory glutamatergic neuronal system.

#### Discussion

In the present study, we demonstrated that the phosphotyrosine adapter protein ShcC/N-Shc is implicated in the modulation of hippocampal synaptic plasticity. However, as described in Introduction, hippocampal LTP may not rely on the Shc-mediated TrkB-Ras/MAPK signaling (Korte et al., 2000; Minichiello et al., 2002). Rather than the Shc/Ras/MAPK pathway, the PLC $\gamma$ /IP3/CaMKIV pathway may be more relevant to the modulation of hippocampal LTP immediately downstream of the TrkB receptor (Minichiello et al., 2002). Thus, our results were unexpected, and we were interested in the novel role of ShcC to modulate the hippocampal LTP underlying learning and memory. We therefore estimate that the role of ShcC in hippocampal synaptic plasticity is independent of the Ras/MAPK pathway from the TrkB receptor and is critical to the modulation of NMDA receptor function, based on the attenuated effect of an NMDA receptor antagonist on LTP expression and the increased tyrosine phosphorylation of the NMDA receptors in the hippocampus of ShcC mutant mice.

#### Role of ShcC/N-Shc in hippocampal synaptic plasticity via interaction with the NMDA receptor

We have shown here that ShcC specifically interacted with the NR2B subunit of the NMDA receptors and Src (or Fyn) of tyrosine kinases in the hippocampus, and these interactions were



**Figure 6.** Interaction of ShcC with the NMDA receptors and the Src family in the hippocampus. *A*, Coimmunoprecipitation with Shc family members in the hippocampus. The immunoprecipitates (IP) obtained with antibodies for ShcA, ShcB, or ShcC were immunoblotted with anti-NR1, -NR2B, or -Src family antibody. *B*, Coimmunoprecipitation with ShcC in the hippocampus after glutamate (Glu) stimulation. Hippocampal slices were treated with glutamate (100  $\mu$ M)/glycine (10  $\mu$ M)/spermidine (1 mM) for 5 min. The immunoprecipitates (IP) prepared with anti-ShcC antibody were immunoblotted with anti-NR2B or -Src family antibody. Data represent mean  $\pm$  SEM ( $n = 4$ ). \* $p < 0.05$  and \*\*\* $p < 0.001$  versus corresponding wild type (+/+).

enhanced by glutamate stimulation. The NR2B subunit is phosphorylated at several tyrosine residues by Src and Fyn (Hisatsune et al., 1999; Nakazawa et al., 2001), and the phosphorylation levels are upregulated by tetanic stimulation to induce hippocampal LTP (Rosenblum et al., 1996; Rostas et al., 1996). Thus, it is plausible that ShcC affects NMDA receptor function by binding to the receptor subunit via its phosphotyrosine binding property in an activity-dependent manner. Therefore, ShcC would regulate the receptor activation in the hippocampal LTP through Src family kinase-mediated tyrosine phosphorylation.

The elevated tyrosine phosphorylation levels of NMDA receptor subunits and normal kinase activity levels of the Src family in the hippocampus of ShcC mutant mice suggest that ShcC is implicated in the dephosphorylation of the receptor subunits. If the phosphorylation of the NMDA receptors is downregulated in the presence of ShcC, a potential role of ShcC could be to recruit a certain protein tyrosine phosphatase to the receptor multicomplex or to activate directly or indirectly a phosphatase for phosphotyrosine residues on the receptor subunits. Thus, ShcC binds



the phosphorylated NMDA receptor subunits and also may modulate the dephosphorylation status of the receptor subunits. Alternatively, if the NMDA receptor phosphorylation is upregulated in the presence of ShcC, the interaction of ShcC with a phosphorylated tyrosine of the receptor subunits may mask other tyrosine residues on the subunits from additional phosphorylation by the Src family. Otherwise, ShcC may inhibit activation of an unknown tyrosine kinase for the receptor subunits. Therefore, ShcC would contribute to the interaction between Src-like tyrosine kinase and a tyrosine phosphatase around the NMDA receptor multicomplex, to modulate the hippocampal synaptic plasticity via the receptor activation.

In general, synaptic plasticity is considered a leading candidate for a cellular mechanism of learning and memory (Bliss and Collingridge, 1993; Malenka and Nicoll, 1999), and a good correlation between NMDA receptor-dependent LTP and spatial learning and memory has been demonstrated (Tsien et al., 1996; Tang et al., 1999). Therefore, the superior hippocampus-dependent learning and memory in ShcC mutant mice would be primarily caused by the enhanced NMDA receptor-dependent hippocampal LTP. As evidence to support the above estimation, the difference in the performance of ShcC mutant mice between the contextual and cued fear conditioning tasks should be mentioned. The contextual associative memory is hippocampus dependent, whereas the cued associative memory is hippocampus independent (Phillips and LeDoux, 1992). Both associative memories also depend on the amygdala (Lavond et al., 1993) and NMDA receptor activation (Davis et al., 1987; Kim et al., 1992). Thus, the enhancement of only the former in ShcC mutant mice suggests the specific activation of the NMDA receptors in the hippocampus of the mutant mice.

However, the enhancement of behavioral performance in ShcC mutant mice was observed not only in the hidden-platform test of the Morris water maze task that depends on the hippocampus but also in the visible-platform test that is not necessarily hippocampus dependent. Thus, the performance of ShcC mutant mice in the present behavioral tasks may not be affected by only a specific improvement of hippocampus-dependent learning and memory. There are several explanations for the better performance of ShcC mutant mice in the latter test (e.g., the alteration of motility, emotionality, and visual acuity). Although there was at least no difference in the motility, especially swimming ability, of ShcC mutant mice, emotionality such as motivation to escape from water may be affected by alterations of NMDA receptor function in the hippocampus, because the alterations are known to influence emotion-associated neuronal circuits in other regions of the brain (e.g., the dopaminergic and serotonergic neuronal systems in the cerebral cortex and striatum) (Mohn et al., 1999; Miyamoto et al., 2001). Currently, there is no evidence that ShcC is involved in emotionality and those neuronal systems. However, because ShcC is expressed in the retinal ganglion cell during perinatal development (Nakazawa et al., 2002), a loss of ShcC may have some influence on the performance of visual acuity. Therefore, there is a need to investigate the emotional and visual performance in ShcC mutant mice.

#### **Upstream and downstream signaling of the ShcC/N-Shc associated with hippocampal synaptic plasticity**

We discussed above that ShcC plays a role in the modulation of hippocampal synaptic plasticity via interaction with the postsynaptic NMDA receptors but not with the BDNF-stimulated TrkB receptors. This idea is consistent with the findings that ShcC accumulates in the PSD (Suzuki et al., 1999) and BDNF is re-

quired for presynaptic but not postsynaptic modulation of LTP in the hippocampal CA3–CA1 synapses (Xu et al., 2000; Zakharenko et al., 2003). However, it remains possible that ShcC is involved in TrkB-mediated hippocampal synaptic plasticity at the postsynapses, because BDNF was taken up by postsynaptic neurons in an activity-dependent manner (Kohara et al., 2001). Thus, the enhanced hippocampal LTP in ShcC mutant mice may be caused in part by alterations of postsynaptic TrkB receptor signaling, for example, through activation of the PLC $\gamma$ -mediated TrkB–IP3/CaMKIV pathway that is proposed to be relevant to hippocampal LTP (Minichiello et al., 2002). More studies are needed to clarify the signaling capabilities of the BDNF-stimulated TrkB receptors in the absence of ShcC and the signaling ability of ShcC as a go-between adapter protein for the TrkB and NMDA receptors, because NMDA receptor activation is frequently associated with TrkB-mediated hippocampal LTP (Suen et al., 1997; Levine et al., 1998). In addition, it is essential to investigate directly the NMDA receptor synaptic responses in ShcC mutant mice, because our findings showed only differences in the contribution of NMDA receptor to hippocampal LTP in the mutant mice.

Similarly to ShcC mutant mice, mice lacking H-Ras showed enhanced hippocampal LTP and tyrosine phosphorylation of the NMDA receptors (Manabe et al., 2000). These enhancements explained why the deficiency of H-Ras increased Src kinase activity and subsequently potentiated the receptor function associated with hippocampal LTP (Thornton et al., 2003). These findings might suggest that ShcC modulates NMDA receptor function for hippocampal LTP via inhibition of Src kinase activity through the Ras family, including H-Ras, because ShcC transmits BDNF-stimulated TrkB receptor signaling to the Ras/MAPK pathway (Nakamura et al., 1998; Liu and Meakin, 2002). In this study, however, Src and Fyn kinase activity were unaffected in the hippocampus of ShcC mutant mice, which was distinct from the case of H-Ras mutant mice.

Hippocampal synaptic modulation by ShcC may also involve other molecules. A novel 250 kDa Rho-GTPase activating protein (GAP) Grit (Nakamura et al., 2002), also termed RICS (Rho GAP involved in the  $\beta$ -catenin–N-cadherin and NMDA receptor signaling) (Okabe et al., 2003) or p250GAP (Nakazawa et al., 2003), is suggested to be involved in modulation of NMDA receptor signaling. Grit was identified originally as a binding partner of ShcC and is involved in neurotrophin-dependent neurite outgrowth via the specific modulation of cytoskeletal actin dynamics (Nakamura et al., 2002). Actin dynamics in dendritic spines have been implicated in hippocampal LTP (Engert and Bonhoeffer, 1999; Matus, 2000). Grit interacted with the NR2B subunit of the NMDA receptors, and this interaction was modulated by the receptor activation (Nakazawa et al., 2003). These findings suggest that Grit regulates the NMDA receptor-dependent actin reorganization in dendritic spines. Thus, the absence of ShcC may also influence the localization of Grit and further affect the postsynaptic remodeling of the cytoskeleton underneath the NMDA receptors, which is associated with hippocampal LTP underlying learning and memory (Milner et al., 1998). It could be that multiple molecules are needed to regulate synaptic function for hippocampal LTP (Sanes and Lichtman, 1999; Inoue and Okabe, 2003); however, ShcC would be a modulatory component of these molecules at the hippocampal synapses.

In summary, our observations revealed that the enhancement of hippocampal LTP in ShcC mutant mice is primarily attributable to an alteration of NMDA receptor function rather than an effect on the TrkB–Shc site. The current study established that the

neural-specific phosphotyrosine adapter protein ShcC/N-Shc is a modulator of hippocampal synaptic plasticity underlying learning and memory.

## References

- Adams JP, Sweatt JD (2002) Molecular psychology: roles for the ERK MAP kinase cascade in memory. *Annu Rev Pharmacol Toxicol* 42:135–163.
- Bliss TV, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. *Nature* 361:31–39.
- Cattaneo E, Pelicci PG (1998) Emerging roles for SH2/PTB-containing Shc adaptor proteins in the developing mammalian brain. *Trends Neurosci* 21:476–481.
- Davis M, Hitchcock J, Rosen JB (1987) Anxiety and the amygdala: pharmacological and anatomical analysis of the fear-potentiated startle paradigm. In: *The psychology of learning and motivation* (Bower GH, ed), pp 263–305. New York: Academic.
- Engert F, Bonhoeffer T (1999) Dendritic spine changes associated with hippocampal long-term synaptic plasticity. *Nature* 399:66–70.
- Hisatsune C, Umemori H, Mishina M, Yamamoto T (1999) Phosphorylation-dependent interaction of the N-methyl-D-aspartate receptor  $\epsilon 2$  subunit with phosphatidylinositol 3-kinase. *Genes Cells* 4:657–666.
- Hollmann M, Heinemann S (1994) Cloned glutamate receptors. *Annu Rev Neurosci* 17:31–108.
- Inoue A, Okabe S (2003) The dynamic organization of postsynaptic proteins: translocating molecules regulate synaptic function. *Curr Opin Neurobiol* 13:332–340.
- Kaplan DR, Miller FD (2000) Neurotrophin signal transduction in the nervous system. *Curr Opin Neurobiol* 10:381–391.
- Kim JJ, Fanselow MS, DeCola JP, Landeira-Fernandez J (1992) Selective impairment of long-term but not short-term conditional fear by the N-methyl-D-aspartate antagonist APV. *Behav Neurosci* 106:591–596.
- Kohara K, Kitamura A, Morishima M, Tsumoto T (2001) Activity-dependent transfer of brain-derived neurotrophic factor to postsynaptic neurons. *Science* 291:2419–2423.
- Kojima T, Yoshikawa Y, Takada S, Sato M, Nakamura T, Takahashi N, Copeland NG, Gilbert DJ, Jenkins NA, Mori N (2001) Genomic organization of the Shc-related phosphotyrosine adapters and characterization of the full-length Sck/ShcB: specific association of p68-Sck/ShcB with pp135. *Biochem Biophys Res Commun* 284:1039–1047.
- Korte M, Minichiello L, Klein R, Bonhoeffer T (2000) Shc-binding site in the TrkB receptor is not required for hippocampal long-term potentiation. *Neuropharmacology* 39:717–724.
- Kutsuwada T, Kashiwabuchi N, Mori H, Sakimura K, Kushiya E, Araki K, Meguro H, Masaki H, Kumashiro T, Arakawa M, Mishina M (1992) Molecular diversity of the NMDA receptor channel. *Nature* 358:36–41.
- Lavond DG, Kim JJ, Thompson RF (1993) Mammalian brain substrates of aversive classical conditioning. *Annu Rev Psychol* 44:317–342.
- Levine ES, Crozier RA, Black IB, Plummer MR (1998) Brain-derived neurotrophic factor modulates hippocampal synaptic transmission by increasing N-methyl-D-aspartate receptor activity. *Proc Natl Acad Sci USA* 95:10235–10239.
- Liu HY, Meakin SO (2002) ShcB and ShcC activation by the Trk family of receptor tyrosine kinases. *J Biol Chem* 277:26046–26056.
- Lu B (2003) BDNF and activity-dependent synaptic modulation. *Learn Mem* 10:86–98.
- Malenka RC, Nicoll RA (1999) Long-term potentiation—a decade of progress? *Science* 285:1870–1874.
- Manabe T, Aiba A, Yamada A, Ichise T, Sakagami H, Kondo H, Katsuki M (2000) Regulation of long-term potentiation by H-Ras through NMDA receptor phosphorylation. *J Neurosci* 20:2504–2511.
- Matus A (2000) Actin-based plasticity in dendritic spines. *Science* 290:754–758.
- Milner B, Squire LR, Kandel ER (1998) Cognitive neuroscience and the study of memory. *Neuron* 20:445–468.
- Minichiello L, Calella AM, Medina DL, Bonhoeffer T, Klein R, Korte M (2002) Mechanism of TrkB-mediated hippocampal long-term potentiation. *Neuron* 36:121–137.
- Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T (2001) Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. *J Neurosci* 21:750–757.
- Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. *Cell* 98:427–436.
- Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994) Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. *Neuron* 12:529–540.
- Morris RG, Garrud P, Rawlins JN, O'Keefe J (1982) Place navigation impaired in rats with hippocampal lesions. *Nature* 24:681–683.
- Nakamura T, Muraoka S, Sanokawa R, Mori N (1998) N-Shc and Sck, two neuronally expressed Shc adapter homologs. Their differential regional expression in the brain and roles in neurotrophin and Src signaling. *J Biol Chem* 273:6960–6967.
- Nakamura T, Komiya M, Sone K, Hirose E, Gotoh N, Morii H, Ohta Y, Mori N (2002) Grit, a GTPase-activating protein for the Rho family, regulates neurite extension through association with the TrkA receptor and N-Shc and CrkL/Crk adapter molecules. *Mol Cell Biol* 22:8721–8734.
- Nakanishi S, Masu M (1994) Molecular diversity and functions of glutamate receptors. *Annu Rev Biophys Biomol Struct* 23:319–348.
- Nakazawa T, Komai S, Tezuka T, Hisatsune C, Umemori H, Semba K, Mishina M, Manabe T, Yamamoto T (2001) Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR  $\epsilon 2$  (NR2B) subunit of the N-methyl-D-aspartate receptor. *J Biol Chem* 276:693–699.
- Nakazawa T, Nakano I, Sato M, Nakamura T, Tamai M, Mori N (2002) Comparative expression profiles of Trk receptors and Shc-related phosphotyrosine adapters during retinal development: potential roles of N-Shc/ShcC in brain-derived neurotrophic factor signal transduction and modulation. *J Neurosci Res* 68:668–680.
- Nakazawa T, Watabe AM, Tezuka T, Yoshida Y, Yokoyama K, Umemori H, Inoue A, Okabe S, Manabe T, Yamamoto T (2003) p250GAP, a novel brain-enriched GTPase-activating protein for Rho family GTPases, is involved in the N-methyl-D-aspartate receptor signaling. *Mol Biol Cell* 14:2921–2934.
- Ohno M, Frankland PW, Chen AP, Costa RM, Silva AJ (2001) Inducible, pharmacogenetic approaches to the study of learning and memory. *Nat Neurosci* 4:1238–1243.
- Okabe T, Nakamura T, Nishimura YN, Kohu K, Ohwada S, Morishita Y, Akiyama T (2003) RICS, a novel GTPase-activating protein for Cdc42 and Rac1, is involved in the  $\beta$ -catenin-N-cadherin and N-methyl-D-aspartate receptor signaling. *J Biol Chem* 278:9920–9927.
- Patapoutian A, Reichardt LF (2001) Trk receptors: mediators of neurotrophin action. *Curr Opin Neurobiol* 11:272–280.
- Phillips RG, LeDoux JE (1992) Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. *Behav Neurosci* 106:274–285.
- Poo MM (2001) Neurotrophins as synaptic modulators. *Nat Rev Neurosci* 2:24–32.
- Rampon C, Tang YP, Goodhouse J, Shimizu E, Kyin M, Tsien JZ (2000) Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. *Nat Neurosci* 3:238–244.
- Ravichandran KS (2001) Signaling via Shc family adapter proteins. *Oncogene* 20:6322–6330.
- Rosenblum K, Dudai Y, Richter-Levin G (1996) Long-term potentiation increases tyrosine phosphorylation of the N-methyl-D-aspartate receptor subunit 2B in rat dentate gyrus *in vivo*. *Proc Natl Acad Sci USA* 93:10457–10460.
- Rostas JA, Brent VA, Voss K, Errington ML, Bliss TV, Gurd JW (1996) Enhanced tyrosine phosphorylation of the 2B subunit of the N-methyl-D-aspartate receptor in long-term potentiation. *Proc Natl Acad Sci USA* 93:10452–10456.
- Sakai R, Henderson JT, O'Bryan JP, Elia AJ, Saxton TM, Pawson T (2000) The mammalian ShcB and ShcC phosphotyrosine docking proteins function in the maturation of sensory and sympathetic neurons. *Neuron* 28:819–833.
- Sanes JR, Lichtman JW (1999) Can molecules explain long-term potentiation? *Nat Neurosci* 2:597–604.
- Silva AJ (2003) Molecular and cellular cognitive studies of the role of synaptic plasticity in memory. *J Neurobiol* 54:224–237.
- Suen PC, Wu K, Levine ES, Mount HT, Xu JL, Lin SY, Black IB (1997) Brain-derived neurotrophic factor rapidly enhances phosphorylation of the postsynaptic N-methyl-D-aspartate receptor subunit 1. *Proc Natl Acad Sci USA* 94:8191–8195.
- Suzuki T, Mitake S, Murata S (1999) Presence of up-stream and down-

- stream components of a mitogen-activated protein kinase pathway in the PSD of the rat forebrain. *Brain Res* 840:36–44.
- Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, Liu G, Tsien JZ (1999) Genetic enhancement of learning and memory in mice. *Nature* 401:63–69.
- Thornton C, Yaka R, Dinh S, Ron D (2003) H-Ras modulates NMDA receptor function via inhibition of Src tyrosine kinase activity. *J Biol Chem* 278:23823–23829.
- Tsien JZ, Huerta PT, Tonegawa S (1996) The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. *Cell* 87:1327–1338.
- Wang YT, Salter MW (1994) Regulation of NMDA receptors by tyrosine kinases and phosphatases. *Nature* 369:233–235.
- Xu B, Gottschalk W, Chow A, Wilson RI, Schnell E, Zang K, Wang D, Nicoll RA, Lu B, Reichardt LF (2000) The role of brain-derived neurotrophic factor receptors in the mature hippocampus: modulation of long-term potentiation through a presynaptic mechanism involving TrkB. *J Neurosci* 20:6888–6897.
- Ying SW, Futter M, Rosenblum K, Webber MJ, Hunt SP, Bliss TV, Bramham CR (2002) Brain-derived neurotrophic factor induces long-term potentiation in intact adult hippocampus: requirement for ERK activation coupled to CREB and upregulation of Arc synthesis. *J Neurosci* 22:1532–1540.
- Yu XM, Askalan R, Keil II GJ, Salter MW (1997) NMDA channel regulation by channel-associated protein tyrosine kinase Src. *Science* 275:674–678.
- Zakharenko SS, Patterson SL, Dragatsis I, Zeitlin SO, Siegelbaum SA, Kandel ER, Morozov A (2003) Presynaptic BDNF required for a presynaptic but not postsynaptic component of LTP at hippocampal CA1–CA3 synapses. *Neuron* 39:975–990.
- Zamanillo D, Sprengel R, Hvalby O, Jensen V, Burnashev N, Rozov A, Kaiser KM, Koster HJ, Borchardt T, Worley P, Lubke J, Frotscher M, Kelly PH, Sommer B, Andersen P, Seeburg PH, Sakmann B (1999) Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. *Science* 284:1805–1811.



ORIGINAL PAPER

## Domain-specific function of ShcC docking protein in neuroblastoma cells

Izumi Miyake<sup>1,2</sup>, Yuko Hakomori<sup>1</sup>, Yoko Misu<sup>2</sup>, Hisaya Nakadate<sup>2</sup>, Nobuo Matsuura<sup>2</sup>, Michiie Sakamoto<sup>3</sup> and Ryuichi Sakai<sup>\*1</sup>

<sup>1</sup>Growth Factor Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; <sup>2</sup>Department of Pediatrics, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagami-hara-shi, Kanagawa 228-8555, Japan; <sup>3</sup>Department of Pathology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

ShcC is a family member of the Shc docking proteins that possess two different phosphotyrosine-binding motifs and conduct signals as Grb2-binding substrates of various receptor tyrosine kinases. We have recently shown that some neuroblastoma cell lines, such as NB-39-nu cells, express a protein complex of hyperphosphorylated ShcC and anaplastic lymphoma kinase (ALK), which is self-activated by gene amplification. Here, we demonstrate that the expression of a mutant ShcC lacking Grb2-binding sites, 3YF-ShcC, significantly impaired the survival, differentiation and motility of NB-39-nu cells by blocking the ERK and Akt pathways. On the other hand, cells overexpressing ShcC or 3YF-ShcC, but not a mutant ShcC that lacks SH2, showed decreased anchorage independency and *in vivo* tumorigenicity, suggesting a novel ShcC-specific suppressive effect through its SH2 domain on cell transformation. Notably, overexpression of ShcC suppressed the sustained phosphorylation of Src family kinase after cell detachment, which might be independent of phosphorylation of Grb2-binding site. It was indicated that the Src/Fyn-Cas pathway is modulated as a target of these suppressive effects by ShcC. Reciprocal change of ShcC expression and phosphorylation observed in malignant neuroblastoma cell lines might be explained by these phosphotyrosine-dependent and -independent functions of ShcC.

*Oncogene* (2005) 0, 000–000. doi:10.1038/sj.onc.1208523

**Keywords:** ShcC; neuroblastoma; dominant-negative form; SH2 domain; Src family kinase

### Introduction

The Shc family of docking proteins plays an essential role in leading cellular signaling to specific downstream molecules such as the Ras-ERK pathway and the phosphatidylinositol 3-kinase (PI3K)-Akt pathway when recruited towards phosphotyrosine residues of various activated RTKs. In mammals, three *shc* genes

have been identified, and their products have been termed ShcA/Shc, ShcB/Sli/Sck and ShcC/Rai/N-Shc (Nakamura *et al.*, 1996a; O'Bryan *et al.*, 1996b; Pelicci *et al.*, 1996). ShcA is ubiquitously expressed in most organs except the adult neural system, whereas ShcB and ShcC proteins are selectively expressed in the neural system within adult mouse tissues.

The Shc family molecules have a unique PTB-CH1-SH2 modular organization. Two phosphotyrosine-binding modules, PTB and SH2 domains, recognize phosphotyrosine-containing polypeptides such as cytoplasmic domains of various activated RTKs (Pelicci *et al.*, 1992; van der Geer *et al.*, 1995). The CH1 domain has several tyrosine phosphorylation sites that recruit other SH2-containing adaptor molecules such as Grb2 (van der Geer *et al.*, 1996; Thomas and Bradshaw, 1997) and a proline-rich stretch of ShcA composing the binding site for the SH3 domains of other proteins including Src, Fyn and Lyn (Weng *et al.*, 1994; Wary *et al.*, 1998). There might be difference in the molecular functions of each Shc family member, although there is not much information on individual roles of Shc families in the neural system and neuronal tumors.

We have recently shown that the expression and tyrosine phosphorylation of Shc family proteins, especially ShcC, are observed in most neuroblastoma cells. Stable association of constitutively activated anaplastic lymphoma kinase (ALK) with the ShcC has been observed in several neuroblastoma cell lines that have extremely high phosphorylation levels of ShcC (Miyake *et al.*, 2002). These cell lines showed malignant phenotypes as for tumorigenicity in nude mice or soft agar colony assay, and notably, ShcC expression is low compared with other neuroblastoma in spite of significantly high phosphorylation state. The *ALK* gene locus was significantly amplified in these cell lines, which results in the constitutive activation of the ALK and most prominent tyrosine phosphorylation of ShcC among several known binding partners of ALK such as PLC $\gamma$  and IRS-1 (Miyake *et al.*, 2002).

ALK protein has the typical structure of an RTK classified into the insulin receptor superfamily. It is dominantly expressed in the normal neural system (Iwahara *et al.*, 1997; Morris *et al.*, 1997), although the biological role of this protein in neuronal cells has not yet been clearly identified. We detected remarkable

\*Correspondence: R Sakai; E-mail: rsakai@gan2.res.ncc.go.jp  
Received 12 October 2004; revised 30 December 2004; accepted 12 January 2005

amplification of the *ALK* gene in three out of 13 neuroblastoma cell lines (Miyake *et al.*, 2002) and a less significant gain of copy numbers in eight out of 85 primary neuroblastoma tissues (Hakomori *et al.*, manuscript in preparation), most of which accompany the amplification of the *N-myc* gene. The three *ALK*-amplified neuroblastoma cell lines showed constitutive activation of full-length *ALK* and the increased local concentration of receptor tyrosine kinases appeared to interfere with signals from other RTKs. It is possible that *ALK*-*ShcC* signal activation has additional effects on the malignant tumor progression of neuroblastoma, probably similar to the mechanism reported in *EGFR* and *Neu/ErbB2* (Andrechek *et al.*, 2000; Pawson *et al.*, 2001).

To clarify the role of hyperphosphorylated *ShcC* in neuroblastoma cells, the 3YF-*ShcC* mutant, which has phenylalanines at three Grb2-binding tyrosines (Y221/222/304) of *ShcC*, was utilized in this study in the expectation of a dominant-negative effect specific for signals originating from the *ShcC*-Grb2 complex. The biological effects of the 3YF-*ShcC* mutant as well as wild-type *ShcC* and the  $\Delta$ SH2 *ShcC* mutant, which lacks the SH2 domain, were analysed to elucidate both Grb2-dependent and -independent functions of *ShcC* in neuroblastoma.

## Results

### *Suppression of ERK1/2 and Akt activation in NB-39-nu cells by expression of 3YF-ShcC*

A neuroblastoma cell line, NB-39-nu, was used in this study because it shows high tumorigenicity and anchorage independency with prominent phosphorylation level of *ShcC* caused by constitutively activated *ALK* kinase. The expression level of *ShcC* is relatively low among the neuroblastoma cell lines examined in our previous study. T7-tagged *ShcC* constructs containing the full length of human *ShcC* cDNA (*ShcC*-wt), a tyrosine-to-phenylalanine mutant for all three putative Grb2-binding sites (3YF-*ShcC*), and the SH2-deletion mutant ( $\Delta$ SH2-*ShcC*) were subcloned into a mammalian expression vector, pcDNA3.1. Multiple independent clones of NB-39-nu cell lines stably expressing these *ShcC* mutants at comparable levels were selected and submitted to biochemical and biological analysis. Results of representative clones are shown in Figure 1a, although basically same results were obtained from other independent clones (data not shown). Tyrosine phosphorylation of the 3YF-*ShcC* was significantly suppressed suggesting that the three tyrosines lost in this mutant are the main phosphorylation sites of *ShcC* in NB-39-nu (Figure 1a). As expected, the complex formation of 3YF-*ShcC* with Grb2 was impaired, regardless of EGF stimulation, compared with that of *ShcC*-wt and  $\Delta$ SH2-*ShcC* (Figure 1c). The activation level of ERK1/2 at 5 min after the EGF stimulation was decreased by expression of 3YF-*ShcC*, while expression of *ShcC*-wt or  $\Delta$ SH2-*ShcC* did not affect the levels of

ERK1/2 activation compared with the control cells transfected only by expression vector (mock) (Figure 1d). The phosphorylation level of Akt at Ser-473 was also suppressed by expression of 3YF-*ShcC*, although not at a similar level as that of cells treated with Wortmannin (Sigma), a PI3K inhibitor (Figure 1e). These analyses were performed using at least two independent clones. It was confirmed that 3YF-*ShcC*-expression has a dominant-negative effect on the PI3K/Akt pathway as well as the Ras/ERK pathway in this neuroblastoma cell line.


### *Expression of 3YF-ShcC increased susceptibility to retinoic acid (RA)-induced apoptosis in NB-39-nu cells*

There were no obvious differences in growth rate among the NB-39-nu clones expressing each *ShcC* mutant (Figure 2a), whereas the rate of [<sup>3</sup>H]-thymidine incorporation of the cell lines expressing 3YF-*ShcC* was slightly lower than that of other cells (Figure 2b).

The cytological analyses of the cells cultured with 10  $\mu$ M of all-*trans*-RA revealed that 3YF-*ShcC* expressing cells were more susceptible to RA-induced apoptosis than the control or *ShcC*-wt-expressing cells (Figure 3a). Treatment of NB-39-nu cells, especially *ShcC*-wt-expressing cells, with RA at a lower concentration of 2.5 or 5  $\mu$ M induced mild neurite formation, flattened, substrate-adherent cells resembling epithelial cells within 48 h (Figure 3b), which is known to be a characteristics of RA-induced morphologic differentiation (Sidell *et al.*, 1983). In contrast, this type of differentiation was not observed in 3YF-*ShcC*-expressing cells. Along with the suppressive effects of 3YF-*ShcC* to the Akt pathway (Figure 1e), these results suggest that phosphorylated *ShcC* plays significant role in survival signals through the putative Grb2-binding sites in NB-39-nu cells.

### *ShcC plays a distinct role in the migration of ALK-ShcC-activated neuroblastoma cells*

Expression of 3YF-*ShcC* significantly suppresses cell migration ability as shown by the wound-healing assay (Figure 4a). A modified Boyden chamber cell-migration assay without Matrigel using fibronectin as a chemoattractant showed the results consistent with those obtained in the wound-healing assay (Figure 4b). A similar assay with Matrigel coating on a chamber filter to evaluate the chemotactic invasive activity of each transfectant also showed decreased invasive activity in 3YF-*ShcC*-expressing cells (Figure 4c). In contrast, *ShcC*-wt expression increased the migration ability of NB-39-nu cells both in wound healing assay and modified Boyden chamber assay without Matrigel (Figure 4a, b), while the  $\Delta$ SH2-*ShcC* expression presented no remarkable effects on the cell motility. The invasive activity of *ShcC*-wt-expressing cells was not significantly high compared to that of the control or of the  $\Delta$ SH2-*ShcC*-expressing cells (Figure 4c).




**Figure 1** NB-39-nu cells stably expressing ShcC mutants analysed by immunoblotting. (a) Expression (upper panel) and tyrosine phosphorylation (lower panel) of ectopic ShcC mutant proteins (mock: control, ShcC: ShcC-wt, 3YF: 3YF-ShcC and ΔSH2: ΔSH2-ShcC) in the NB-39-nu cells. (b) Expression (upper panel) and tyrosine phosphorylation (lower panel) of both endogenous ShcC and ectopic ShcC mutants in NB-39-nu cells. (c) The complex formation of Grb2 with ShcC (lower panel) or ectopic ShcC mutants (upper panel) was analysed. (d) The activation of ERK1/2 in ShcC mutant cells. (e) Akt (Ser473) phosphorylation in ShcC mutant cells in a tissue culture medium with 10% fetal calf serum (FCS). For the negative control, the cells were treated with 1 μM of Wortmannin for 2 h. EGF stimulations were performed as described in Materials and methods. Lysates were duplicated and detected by the antibodies shown in the figure

#### Expression of ShcC-wt or 3YF-ShcC has a negative effect on the transforming activity of NB-39-nu cells

Cells expressing ShcC-wt or 3YF-ShcC tend to grow to confluence with a monolayer appearance, making a clear difference from original NB-39-nu cells that tend to form cell aggregations on the culture dishes (Figure 5a). In addition, control NB-39-nu cells and ΔSH2-ShcC-expressing cells form a considerable number of colonies in soft agar (Figure 5b), which is significantly suppressed by the expression of ShcC-wt or 3YF-ShcC (Figure 5b). These results indicate that ShcC-wt or 3YF-ShcC have inhibitory effect on the transforming activity of NB-39-nu cells, especially anchorage-independent growth. Since the overexpression of ShcC had no significant effect on the activation of ERK1/2 or Akt in our experiment, it was suggested that a unique signaling pathway rather than classical Grb2-Ras pathway is involved in this phenomenon.

Src family kinases (SFKs) are well known to be associated with the ability to induce cellular transformation including anchorage independency (Parsons and Weber, 1989; Windham *et al.*, 2002). During the

investigation of ShcC mutant cells in the suspension state, we noticed that the sustained activation of both Fyn and c-Src observed in the control cells and ΔSH2-ShcC-expressing cells was suppressed by the expression of ShcC-wt or 3YF-ShcC (Figure 6a, b) at 24 h after cell detachment. Especially, the condition of phosphorylation of Fyn at suspension culture well correlated with anchorage independency of NB-39-nu sublines (Figure 6a). Tendency of phosphorylation of Src Tyr-416, which indicates the kinase activation of SFKs, is consistent with these results (Figure 6c). Phosphorylation of Cas, a main substrate of SFKs, in a suspended condition has recently been associated with the anchorage-independent growth of cancer-like lung adenocarcinoma (Wei *et al.*, 2002). Sustention and temporary elevation of the Cas phosphorylation was also observed specifically in the original NB-39-nu cells, control and ΔSH2-ShcC-expressing cells, whereas there was a marked decrease of the phosphorylation level of Cas in ShcC-wt- and 3YF-ShcC-expressing cells (Figure 6d, e). Treatment of NB-39-nu control cells with PP2, a Src-specific inhibitor, suppressed the phosphorylation of Cas both in an attached and suspended condition, suggesting



**Figure 2** Growth rate and proliferation ability of ShcC mutant cells *in vitro*. (a) ShcC mutant cells cultured in a normal medium with 10% FCS by 30-mm dishes were counted at the indicated time points. The results represent the average values ( $\pm$ s.d.) of three replicated experiments for each clone. (b) ShcC mutant cells stimulated with none (gray bar) or EGF (black bar) were treated with [<sup>3</sup>H]thymidine to the culture medium as described in Materials and methods. The graph represents the average values ( $\pm$ s.d.) from an experiment performed in triplicate. NB-39-nu clones are described as: v1 and v2 (control), w1 and w2 (expressing ShcC-wt), m1 and m2 (expressing 3YF), d1 and d2 (expressing  $\Delta$ SH2)

that the anchorage-independent phosphorylation of Cas is associated with the activity of the SFKs (Figure 6f).

The activation of ERK1/2 or Akt was similarly suppressed by suspension culture for 24 h regardless of the expression of each ShcC mutants although the basal level is lower in 3YF-ShcC clones (Supplementary Figure A). There were no difference in phosphorylation level of FAK and paxillin, which plays an important role in regulating the signals from the extracellular matrix (ECM) and organizing the actin-cytoskeleton, by expressing ShcC-wt, showing a similar level of decrease in the suspended condition (Supplementary Figure B). In summary, it was confirmed in this system that the

constitutive activation of SFKs, such as Fyn and c-Src, and phosphorylation of Cas in suspended cells, but not other components of integrin signals such as FAK, is strictly linked to the anchorage independency of NB-39-nu cells, closely related with ShcC mutants expression. Furthermore, we detected interaction between ShcC-wt and some of SFKs following the stimulation (Figure 6g), indicating a novel biological interaction of ShcC with SFK, as suggested for ShcA in integrin pathway (Wary *et al.*, 1996; Giancotti, 1997)


#### *Loss of tumorigenicity of NB-39-nu-expressing ShcC-wt or 3YF-ShcC in mouse subcutaneous tissues*

To investigate these antitransforming effects of ShcC-wt and 3YF-ShcC *in vivo*, the tumorigenicity of NB-39-nu cells expressing each mutant in nude mice was evaluated. Tumors generated by eight independent injections of each mutant were analysed in weight and histology at 4 weeks after subcutaneous injection. The results revealed a marked reduction in sizes of tumors from the cells expressing either ShcC-wt or 3YF-ShcC at this time, but not of tumors from the control cells or cells expressing  $\Delta$ SH2-ShcC (Figure 7a).

The tumors from the control, ShcC-wt-expressing and  $\Delta$ SH2-ShcC-expressing cells presented a hypervascular appearance (Figure 7a: upper panel), which has the histological characteristics of almost equal-sized cells with a regular arrayed pattern, high nuclear-to-cytoplasmic (N/C) ratio and chromatin-rich nucleuses (Figure 7b). On the other hand, the tumors from the 3YF-ShcC-expressing cells were hypovascular and histologically distinct from the other mutants, showing rather unequal-sized cells with an irregular arrayed pattern, a lower N/C ratio, few mitosis and decreased nucleus density. In accordance with this, staining by a proliferation marker, Ki-67, or a mitotic activity marker, cyclin A, markedly decreased in the tumors from 3YF-ShcC-expressing cells (Figure 7b), showing that the cell cycle progression was significantly suppressed by 3YF-ShcC *in vivo*, compared with the analysis by [<sup>3</sup>H]-thymidine incorporation *in vitro* (Figure 2b). TUNEL staining showed no marked difference in cell apoptosis among each tumor tissue (data not shown). These results suggest that the antitumorigenic activity of the 3YF-ShcC-expressing cells *in vivo* accompanies the regulation of cell proliferation, which is distinct from the impairment of tumorigenicity by expression of ShcC-wt.

#### Discussion

In our previous report, the biological effects of constitutively activated signals of ALK-ShcC on the tumorigenesis of neuroblastoma cells remain to be investigated. Here, we demonstrated that the proliferation, survival and cell migration of these neuroblastoma cells were dependent on the signals via ShcC-Grb2 pathway, downstream of ALK. Additionally, over-expressed ShcC has a suppressive effect on the



**Figure 3** Effects of ShcC mutants on apoptosis and differentiation of NB-39-nu cells induced by all-*trans* retinoic acid (RA). (a) TUNEL analysis of ShcC mutant cells were performed as described in Materials and methods. Bar: 100  $\mu$ m (upper panel). TUNEL-positive cells, the prominent dark positive cells, are counted for every 1000 cells for each slide, and three different slides were analysed for each sample. The graph represents the results (expressed as mean  $\pm$  s.d.) of three observations (lower panel). (b) RA-induced morphological change of NB-39-nu cells expressing ShcC mutants. The cells were grown for 48 h in RPMI 1640 with 10% FCS containing 2.5  $\mu$ M of RA and examined by phase-contrast microscopy (upper panel). Actin filaments stained with FITC-labeled phalloidin were visualized with a confocal fluorescence microscope (lower panel)


anchorage-independent growth of these cells via its SH2 domain and this regulation is closely associated with the regulation of c-Src and Fyn tyrosine kinases.

The fact that 3YF-ShcC significantly suppressed the activity of both ERK1/2 and Akt, suggesting that ShcC, among signaling pathways originating from activated ALK, predominantly regulates these signals through binding to Grb2. Our recent study also shows that the suppression of activated ALK using the RNA interference technique (RNAi) reduces the phosphorylation of ShcC, ERK1/2 and Akt, and induces the apoptotic cell death of NB-39-nu cells (Hakomori *et al.*, manuscript in preparation). The ERK and Akt pathways are key regulators of cell proliferation, survival and differentiation. Cells expressing 3YF-ShcC become more susceptible to RA-induced apoptosis presumably due to inhibition of the Akt pathway. It has recently


been shown that ShcC is physiologically involved in the regulation of the PI3K/Akt pathway as a downstream effector of the ligand-stimulated Ret receptor in neuroblastoma cells (Pelicci *et al.*, 2002). This study confirms that the survival of NB-39-nu cells is regulated by the signals downstream of ShcC. The 3YF-ShcC also causes inhibition of cell motility, while overexpressed ShcC significantly increases the ability of cell migration, indicating that ShcC positively affects the regulation of cell migration. Previously, ShcA was shown to be closely related with cell motility via the MAPK pathway (Collins *et al.*, 1999; Gu *et al.*, 1999), but the association of ShcC with the ability of cell migration has not been investigated.

The expression of 3YF-ShcC had a suppressive effect on the proliferation of NB-39-nu cells cultured *in vitro* and more significantly on the cell cycle progression of






**Figure 4** Expression of ShcC-wt significantly promotes the ability of cell migration in NB-39-nu cells. (a) Wound-healing assay for ShcC mutant cells. Photographs of the cells taken 48 h after wounding under a microscope. Bar: 200  $\mu$ m. (b) Photographs (upper panel) and graph (lower panel) of ShcC mutant cells that have migrated through the filter by modified Boyden chamber cell migration assay. The graph represents the results (expressed as mean  $\pm$  s.d.) of the experiments performed in triplicate. (c) Photographs (upper panel) and a graph (lower panel) of the results from cell invasion assay



**Figure 5** Evaluation of *in vitro* transforming activity in NB-39-nu cells expressing ShcC mutants. (a) Tendency for ShcC mutant cells to form cell aggregations on the dish surface as described in Materials and methods. Photographs of each dish were taken with a microscope at a magnification of  $\times 40$  (upper panel). The graph represents the mean values ( $\pm$  s.d.) of three independent experiments (lower panel). (b) Anchorage-independent growth of ShcC mutant cells was evaluated by assaying colony formation in soft agar (performed as described in Materials and methods). The results represent the average values ( $\pm$  s.d.) of three replicated experiments




**Figure 6** Anchorage-independent activation of Src family kinases (SFKs) and tyrosine phosphorylation of Cas in NB-39-nu is affected by the expression of ShcC. The cell suspension culture of ShcC mutant cells was essentially performed as described in Materials and methods. A: attached cells. S: cells in a suspended condition. Lysates were duplicated and detected by immunoprecipitation and Western analysis. (a, b and c) Cells cultured for 24 h in adherent or suspended conditions were analysed with the antibodies against each Src family kinase shown in the figure. Anti-phospho-Src Y416 recognizes all Src family members phosphorylated at the tyrosine corresponding to Tyr416 of avian Src. (d) Same analysis performed as (a) (b) and (c) using the antibodies against for phospho-460Y of Cas ( $\alpha$ P-Cas460Y) and Cas protein ( $\alpha$ Cas). (e) Time course of tyrosine phosphorylation of Cas in each ShcC mutant cells cultured in suspension for the indicated time periods. (f) Effect of Src inhibitor, PP2, on the tyrosine phosphorylation of Cas in NB-39-nu control cells. The cells cultured for 24 h were harvested following treatment with 10  $\mu$ M of PP2 for 2 h. As a negative control, the same dose of PP3 was used in place of PP2. (g) ShcC forms complex with SFKs following the stimulation of fibronectin. Lysates of mock cells and ShcC-wt cells were analysed after the stimulation with EGF or fibronectin as described in Materials and methods. -: serum free without stimulation; E: stimulated by EGF; F: stimulated by fibronectin. Ig: immunoglobulin. Anti-pan-Src antibody (SRC2) reacts with c-Src p60, Yes p62, Fyn p59, c-Fgr p55 and c-Src2. closed arrowhead: SFK; open arrowhead: p52 ShcC

the nude mouse tumor. These data suggest that ShcC positively regulates the cell proliferation of neuronal tumor cells as well as ShcA, which has been reported to affect the tumor growth in nude mice using breast cancer cell lines (Stevenson *et al.*, 1999).

The overexpression of ShcC-wt endowed NB-39-nu cells with several characteristics. Other than the enhancement of cell migration and neurite outgrowth, which is consistent with previous study (Collins *et al.*, 1999; Pelicci *et al.*, 2002), the observation that ShcC-wt-expressing cells were impaired for anchorage-independent growth and tumorigenicity suggests a novel function of ShcC. Taking into account that the expression of 3YF-ShcC but not  $\Delta$ SH2-ShcC showed similar effects, the SH2 domain of ShcC may be responsible for this unique function of ShcC, distinct from ShcA. In addition, the least changes in ERK1/2 or Akt activation by overexpression of ShcC-wt suggest

that this function might be independent of phosphorylation of Grb2-binding sites or the activation levels of downstream targets. There are reports showing different binding specificity towards phosphotyrosine-containing motifs among Shc families (O'Bryan *et al.*, 1996a,b; Pelicci *et al.*, 1996). It is crucial to identify the molecules associating with the SH2 domain of ShcC in neuroblastoma cells to elucidate the mechanism of these SH2-mediated effects of ShcC.

The smaller size of the nude mouse tumors due to the expression of ShcC-wt, regardless of mild changes in cell proliferation as both tumor tissue and culture cells, may also reflect suppression of anchorage independency (Freedman and Shin, 1974; Kumar, 1998), which results in the loss of the majority of the injected cells by anoikis before they start forming tumors. The anchorage independency of NB-39-nu mutants well corresponded to the sustained phosphorylation levels of c-Src, Fyn



**Figure 7** Nude mouse tumors derived from ShcC mutant cells. (a) Photographs of tumors from nude mice at three weeks after subcutaneous injection of ShcC mutant cells (upper panel). Tumorigenicity shown by the average weight ( $\pm$ s.d.) of the eight tumors derived from each clone (lower panel). Two independent clones are analysed for each ShcC mutant. Bar: 10 mm (b) Photographs of a cross-section of each tumor tissue using a microscope at a magnification of  $\times 400$ . HE: tumor tissues stained with hematoxylin and eosin; Ki-67 and cyclin-A: tumor tissues immunostained against Ki-67 and cyclin-A, respectively (upper panels). The proliferating activity of each tumor was defined as the labeling index of Ki-67 by counting the positive stained cells per 1000 tumor cells. The data show the average scores  $\pm$  s.d. of the positive cells in three different areas of each slide (lower panel). NB-39-nu clones are described as: v1 and v2 (control), w1 and w2 (expressing ShcC-wt), m1 and m2 (expressing 3YF-ShcC), d1 and d2 (expressing  $\Delta$ SH2-ShcC)

and Cas after cell detachment, suggesting that the expression of ShcC-wt has a negative effect on anchorage independency due to the suppression of the SFK-Cas pathway (Figure 6). It is possible that ShcC-SH2 plays a competitive role with YDYV in the Src-binding domain of Cas, judging from the consensus motifs binding to ShcC-SH2 (O'Bryan *et al.*, 1996a, b), although this association was not detected by usual immunoprecipitation experiments (data not shown). On the other hand, the fact that ShcC forms the complex with SFK in this study indicates that there might be a role of association between SFK and ShcC in the regulation of tyrosine kinase activity of SFK. The fact that malignant neuroblastoma cell lines with hyperphosphorylated ShcC frequently have lower expression level of ShcC (Miyake *et al.*, 2002) might indicate additive effects of hyperphosphorylation and downregulation of ShcC on phenotype of neuroblastoma. There is the possibility that an unknown mechanism causes downregulation of ShcC, which is hyperphosphorylated by

receptor stimulation, and eventually induces malignant transition of tumors.

We have shown in this study that hyperphosphorylated ShcC in neuroblastoma cells plays an essential role in regulating cellular proliferation, survival, migration and transformation, and each domain of ShcC might differentially regulate these physiological functions. Controlling these domain-mediated signals could be a target in restricting the progression and metastasis of neuroblastoma cells.

## Materials and methods

### Plasmid constructions

The full-length human ShcC cDNA for transfection was donated by Dr T Nakamura (Nakamura *et al.*, 1996b), and inserted into a mammalian expression vector pcDNA3.1. Tyrosine-to-phenylalanine mutations were introduced in the ShcC cDNAs by *in vitro* site-directed mutagenesis, which changed Y221/222 and Y304 to three phenylalanines (3YF-ShcC). The SH2 domain (amino acid 379–472)-deleted form of

ShcC ( $\Delta$ SH2-ShcC) was also generated. All parts amplified by PCR were verified by sequencing.

#### Cell culture, transfection

NB-39-nu cells were used in our previous report (Miyake *et al.*, 2002). The stable expression of ShcC mutants, the full-length of ShcC (ShcC-wt), 3YF-ShcC and  $\Delta$ SH2-ShcC in NB-39-nu cells were obtained by transfection using Fugene™ 6 transfection reagent (Roche Molecular Biochemicals) according to the manufacturer's instructions. Then, cell clones were obtained from individual G418-resistant colonies and subjected to Western blot screening using the T7 tag antibody (Novagen). These cells were cultured in an RPMI 1640 medium with 10% FCS (Sigma) at 37°C in 5% CO<sub>2</sub>. A suspension culture of the cells was essentially performed according to a previously published procedure (Folkman and Moscona, 1978; Frisch and Francis, 1994; Wang and Sheibani, 2002). In this study, LOW-CELL-BINDING 90-mm-Petri dishes treated with 2-Methacryloxyethyl Phosphorylcholine (MPC) (Nalge Nunc International) were used instead of poly-HEMA-coated dishes. The cells were grown to confluence in tissue culture dishes, and were then trypsinized and plated at a concentration of  $1 \times 10^6$  cells/90 mm dish into MPC-treated Petri dishes and cultured for 0–48 h. The cells were then collected by pipetting, washed by PBS and extracted with PLC-lysis buffer (Rozakis-Adcock *et al.*, 1993) for the Western analysis.

#### Preparation of specific antibodies, cell stimulation, immunoprecipitation and immunoblotting

The polyclonal antibodies against the CH1 domains of ShcC (amino acid 306–371) and against Cas protein ( $\alpha$ Cas) were prepared as described (Sakai *et al.*, 1994, 2000). A phospho specific polyclonal antibody against Cas ( $\alpha$ P-Cas460Y) was generated by immunizing rabbits with a synthetic peptide, CAEDV(pY)DVP, which is a representative of the repetitive tyrosine-containing motifs in the substrate domain of Cas, after being conjugated with thyroglobulin. Other antibodies were purchased as follows: anti-phosphotyrosine antibody (4G10) (Upstate Biotechnology, Inc), anti-p44/42 MAPK (ERK1/2) and anti-phospho-p44/42 MAPK (phospho-ERK1/2) antibodies (BioLabs), anti-Akt and anti-phospho-Akt (Ser473) antibodies (Cell Signaling), anti-c-Src antibody (Upstate Biotechnology, Inc.), anti-phospho Src family (Tyr416) antibody (Cell Signaling), anti-Fyn antibody and anti-pan-Src antibody (SRC2) (SantaCruz Biotechnology, Inc.). As secondary antibodies, horseradish peroxidase (HRP)-conjugated anti-rabbit and anti-mouse Ig (Amersham) were used. Cell-stimulation analysis with epidermal growth factor (EGF; Wako) was performed as described. The cells were starved for 24 h and treated for 5 min with EGF (100 ng/ml) (Miyake *et al.*, 2002). As for stimulation with fibronectin, cultured cells were starved for 24 h then trypsinized without FCS and after the suspending condition for 30 min, seeded onto fibronectin (10  $\mu$ g/ml)-coated dishes and harvested after 1 h using PLC lysis buffer. Control cells were harvested before the attachment on the fibronectin-coated surface. The immunoprecipitation and Western analysis were performed using the procedure described in the previous report (Miyake *et al.*, 2002).

#### Evaluation of tendency to form cell aggregations on dish surface

Cells were seeded onto plastic dishes ( $1 \times 10^6$  cells per 100-mm diameter dish). After 5 days, distinctive colonies of cell aggregations proliferated independently of the attachment to the dish surface, and each of them consisted of more than 10

cells per dish. The data were obtained from three independent experiments.

#### Soft agar colony-formation assay

Anchorage-independent growth was determined by assaying colony formation in soft agar as described in the previous report (Honda *et al.*, 1998). Briefly,  $10^5$  trypsinized cells were resuspended in DMEM containing 10% FCS and 0.4% Sea Plaque GTG agarose (Bioproduct) and poured onto bottom agar containing 10% FCS and 0.53% agarose in 6-cm culture dishes. The cells were then incubated at 37°C with 5% CO<sub>2</sub>. After 14 days, colonies containing more than five cells were counted under the microscope.

#### Wound-healing assay

A wound-healing assay was performed according to the method used previously (Honda *et al.*, 1999). Briefly, cells were grown to confluence in Matrigel-coated plastic culture dishes, and a wound was made using a sterile micropipette tip. Cell movement was assessed 24 and 48 h after wounding under the microscope at a magnification of  $\times 100$ .

#### Cell migration and invasion assay

Cell invasion was analysed according to the procedure of the Boyden chamber cell migration assay with some modification (Honda *et al.*, 1999), using a FALCON™ Cell Culture Insert, a chamber with a pore size of 8  $\mu$ m (Becton Dickinson Labware) whose interior was filled with a plug of 10  $\mu$ g Matrigel (IWAKI) per filter. A total of  $1 \times 10^5$  cells in 200  $\mu$ l of serum-free medium were plated in the Matrigel chamber, and a serum-free medium containing 50  $\mu$ g/ml of fibronectin was placed in the 24-well plate as a lower chamber, then incubated for 12 h at 37°C in 5% CO<sub>2</sub>. The number of cells migrated through the Matrigel to the underside of the filter was counted under the microscope. The same procedure was performed without Matrigel coating for the analysis of cell migration.

#### Apoptosis of neuroblastoma cells induced by all-trans RA

Cells, were seeded into 24-well tissue culture plates at a density of  $5 \times 10^4$  cm<sup>-2</sup> and cultured in the presence of the indicated concentration of RA (all-trans form; Sigma) dissolved in 70% ethanol. Control cultures were treated with the same concentration of ethanol. To identify RA-induced apoptotic reaction, TUNEL (TdT-mediated dUTP-biotin nick end labeling) was performed according to the manufacturer's instructions (In Situ Cell Death Detection, POD; Roche) as described by Gavrieli *et al.* (1992). The cells were counterstained with hematoxylin-eosin.

#### [<sup>3</sup>H]thymidine incorporation assay

This was performed essentially as described previously (McNeil *et al.*, 1985). A total of  $2 \times 10^4$  cells were seeded onto 24-well dishes and cultured for 48 h and shifted to a serum-free medium, and then 24 h later were followed by overnight stimulation with 100 ng/ml EGF. [<sup>3</sup>H]thymidine (1  $\mu$ Ci/ml) was added for the last 4 h of incubation. The amount of incorporated [<sup>3</sup>H]thymidine radioactivity was measured by liquid scintillation counting. Results are expressed as disintegrations per minute of incorporated [<sup>3</sup>H]thymidine per well.